In a series of impactful events,
Novo Holdings closes a $16.5 billion acquisition of
contract manufacturer Catalent. The deal was sealed
offering a 47.5% premium to shareholders. As part of the changes,
Catalent has also agreed to sell its Somerset oral solids facility. This major transaction between
Catalent (CTLT) and Novo Holdings (NVO) has
received unconditional approval from the European Commission. In anticipation,
Catalent saw a gain in its stock, with its sale to Novo Holdings predicted to close soon. However, a shift in the financial landscape caused
Lennox to join the S&P 500 Index, replacing Catalent. The acquisition faced some hurdles as
US Senator Warren called for scrutiny and
Consumer groups asked FTC to block it. Eventually, the
approval came from EU regulators, and the
Catalent stockholders approved the buyout by Novo Holdings. Notably,
Novo Nordisk will raise capex if the Catalent deal is not completed, as stated by their CFO. Amidst this,
Catalent successfully completed a $25 Million expansion of its Clinical Supply Facility in Schorndorf, Germany. The influx of information indicates a bright future for both companies.
Catalent CTLT News Analytics from Mon, 03 Feb 2020 08:00:00 GMT to Mon, 03 Feb 2025 15:52:30 GMT -
Rating 8
- Innovation 2
- Information 8
- Rumor -1
